Aytu BioPharma Inc (AYTU)
1.54
-0.20
(-11.75%)
USD |
NASDAQ |
Nov 14, 16:00
1.54
0.00 (0.00%)
After-Hours: 20:00
Aytu BioPharma Enterprise Value: 5.853M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 5.853M |
| November 12, 2024 | 5.803M |
| November 11, 2024 | 6.007M |
| November 08, 2024 | 5.207M |
| November 07, 2024 | 6.285M |
| November 06, 2024 | 6.437M |
| November 05, 2024 | 6.499M |
| November 04, 2024 | 6.868M |
| November 01, 2024 | 7.037M |
| October 31, 2024 | 6.929M |
| October 30, 2024 | 7.360M |
| October 29, 2024 | 7.390M |
| October 28, 2024 | 7.928M |
| October 25, 2024 | 8.434M |
| October 24, 2024 | 8.324M |
| October 23, 2024 | 8.246M |
| October 22, 2024 | 8.712M |
| October 21, 2024 | 8.835M |
| October 18, 2024 | 9.204M |
| October 17, 2024 | 9.204M |
| October 16, 2024 | 9.189M |
| October 15, 2024 | 9.204M |
| October 14, 2024 | 9.020M |
| October 11, 2024 | 8.897M |
| October 10, 2024 | 8.897M |
| Date | Value |
|---|---|
| October 09, 2024 | 8.651M |
| October 08, 2024 | 9.573M |
| October 07, 2024 | 9.512M |
| October 04, 2024 | 9.573M |
| October 03, 2024 | 9.881M |
| October 02, 2024 | 10.07M |
| October 01, 2024 | 9.573M |
| September 30, 2024 | 9.573M |
| September 27, 2024 | 9.635M |
| September 26, 2024 | 12.64M |
| September 25, 2024 | 10.07M |
| September 24, 2024 | 10.07M |
| September 23, 2024 | 9.758M |
| September 20, 2024 | 10.19M |
| September 19, 2024 | 9.881M |
| September 18, 2024 | 10.31M |
| September 17, 2024 | 10.68M |
| September 16, 2024 | 10.93M |
| September 13, 2024 | 10.99M |
| September 12, 2024 | 10.62M |
| September 11, 2024 | 10.56M |
| September 10, 2024 | 10.37M |
| September 09, 2024 | 10.07M |
| September 06, 2024 | 9.819M |
| September 05, 2024 | 9.881M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.837M
Minimum
Sep 14 2023
176.01M
Maximum
Mar 24 2020
41.73M
Average
14.56M
Median
Enterprise Value Benchmarks
| enVVeno Medical Corp | 11.24M |
| Bristol-Myers Squibb Co | 160.18B |
| Telesis Bio Inc | 27.26M |
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.617M |
| Revenue (Quarterly) | 17.98M |
| Total Expenses (Quarterly) | 19.50M |
| EPS Diluted (Quarterly) | -0.82 |
| Gross Profit Margin (Quarterly) | 66.23% |
| Profit Margin (Quarterly) | -25.68% |
| Earnings Yield | -185.7% |
| Normalized Earnings Yield | -106.12 |